

Press Release

AstraZeneca K.K.
Daiichi Sankyo Co., Ltd.

Transfer of Distribution Rights and End of Joint Sales Promotion for Proton Pump Inhibitor Nexium® Capsule 10 mg/20 mg and Nexium® Granules for Suspension 10 mg/20 mg in Japan

Tokyo, Japan (March 12, 2021) –AstraZeneca K.K. (headed by Representative Director and President Stefan Woxstrom; headquartered in Chuo Ward, Tokyo) and Daiichi Sankyo Co., Ltd. (headed by Representative Director, President, and Chief Executive Officer Sunao Manabe; headquartered in Chuo Ward, Tokyo) announced today that Daiichi Sankyo will transfer the marketing and distribution rights for the proton pump inhibitor Nexium® Capsule 10 mg and 20 mg and Nexium® Granules for Suspension 10 mg and 20 mg (esomeprazole magnesium, hereinafter, Nexium) to AstraZeneca, and the two companies will end joint sales promotion on September 14, 2021.

AstraZeneca will market, distribute, and promote Nexium in Japan from September 15, 2021.

The transfer of marketing and distribution rights and the end of joint sales promotion will occur upon termination of the agreement for the distribution and joint sales promotion of Nexium in Japan that the two companies signed in 2010.

Nexium is a proton pump inhibitor that acts to suppress gastric acid secretion. Indications include gastric acid-related diseases, such as reflux esophagitis. It was launched in Japan in September 2011. AstraZeneca is the manufacturer and Daiichi Sankyo is the distributor in Japan. The two companies have jointly conducted sales promotion.

With a view to ensuring a smooth transfer, the two companies will continue to work together to maintain stable drug supply, provide and collect information on the product, and promote its proper use until the transfer is completed.

Products to be transferred

Nexium® Capsule 10 mg

Nexium® Capsule 20 mg

Nexium® Granules for Suspension 10 mg

Nexium® Granules for Suspension 20 mg

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter [@AstraZeneca](https://twitter.com/AstraZeneca).

In Japan, AstraZeneca is actively working to further contribute to the health and medical development of patients with primary focus on Oncology, Cardiovascular, Renal and Metabolism, and Respiratory fields.

For more information, please visit <https://www.astrazeneca.co.jp>

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

For further information and inquiries	
Corporate Affairs AstraZeneca K.K.	Contact: Miyako Kurakami Tel.: 080-4019-8375 / 03-6268-2800 JPN.Ex.Comm@astrazeneca.com
Corporate Communications Department Daiichi Sankyo Co., Ltd.	Tel.: 03-6225-1126